InhaleRx Advances Clinical Trial for Panic Disorder Treatment

InhaleRx Limited ( (AU:IRX) ) has issued an announcement.

InhaleRx Limited has announced the execution of a Study Order with iNGENū CRO Pty Ltd for a Phase 1 clinical trial of its drug candidate, IRX-616a, aimed at treating Panic Disorder. This milestone signifies a crucial advancement in the clinical development of IRX-616a, highlighting the company’s commitment to accelerating its clinical trial programs. The trial, which will be conducted in Adelaide, Australia, will assess the safety and efficacy of a cannabidiol inhaler in healthy volunteers. The company has secured funding to support its clinical development plans, positioning IRX-616a as a potential solution for the unmet need of rapid onset therapies for Panic Disorder.

More about InhaleRx Limited

InhaleRx Limited is an Australian clinical stage biotechnology company focused on developing rapid onset, inhaled therapies to address unmet medical needs in the pain management and mental health sectors. The company aims to achieve U.S. FDA approval through efficient regulatory pathways and is exploring significant economic opportunities in areas such as Breakthrough Cancer Pain and Panic Disorder.

YTD Price Performance: -55.00%

Average Trading Volume: 178,282

Technical Sentiment Signal: Buy

Current Market Cap: A$3.84M

See more data about IRX stock on TipRanks’ Stock Analysis page.